18:57 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Keytruda under Priority Review for first-line squamous NSCLC

Merck & Co. Inc. (NYSE:MRK) said FDA accepted and granted Priority Review to an sBLA for Keytruda pembrolizumab plus carboplatin/paclitaxel or Abraxane nab-paclitaxel as first-line treatment of metastatic squamous non-small cell lung cancer regardless of...
17:57 , Jul 2, 2018 |  BC Extra  |  Company News

Keytruda under Priority Review for first-line squamous NSCLC

Merck & Co. Inc. (NYSE:MRK) said FDA accepted and granted Priority Review to an sBLA for Keytruda pembrolizumab plus carboplatin/paclitaxel or Abraxane nab-paclitaxel as first-line treatment of metastatic squamous non-small cell lung cancer regardless of...
03:05 , Jun 30, 2018 |  BioCentury  |  Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with the...
15:33 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Keytruda monotherapy benefit extended to low PD-L1 expression, though doubts linger

Detailed data from the Phase III KEYNOTE-042 trial showed that Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) given as monotherapy in the first-line setting could be further extended to treat non-small cell lung cancer...
15:23 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Phase III squamous NSCLC survival readouts at ASCO for Keytruda, Tecentriq

Merck & Co. Inc. (NYSE:MRK) and Roche (SIX:ROG; OTCQX:RHHBY) each reported survival data from Phase III trials of their checkpoint inhibitors Keytruda pembrolizumab and Tecentriq atezolizumab, respectively, as first-line treatment of squamous non-small cell lung...
18:29 , Jun 4, 2018 |  BC Extra  |  Clinical News

Squamous NSCLC survival readouts at ASCO for Keytruda, Tecentriq

Merck & Co. Inc. (NYSE:MRK) and Roche (SIX:ROG; OTCQX:RHHBY) each reported survival data from Phase III trials of their checkpoint inhibitors Keytruda pembrolizumab and Tecentriq atezolizumab, respectively, as first-line treatment of squamous non-small cell lung...
11:31 , Jun 3, 2018 |  BC Extra  |  Clinical News

Keytruda monotherapy benefit extended to low PD-L1 expression, though doubts linger

Detailed data from the Phase III KEYNOTE-042 trial showed that Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) given as monotherapy in the first-line setting could be further extended to treat non-small cell lung cancer...
18:06 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Genentech's Tecentriq meets in third Phase III for first-line NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said Tecentriq atezolizumab met the co-primary endpoints of improving progression-free survival (PFS) and overall survival (OS) in the Phase III IMpower130 trial as first-line treatment of stage...
15:07 , May 29, 2018 |  BC Extra  |  Clinical News

Genentech's Tecentriq meets in third Phase III for first-line NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said Tecentriq atezolizumab met the co-primary endpoints of improving progression-free survival (PFS) and overall survival (OS) in the Phase III IMpower130 trial as first-line treatment of stage...
15:29 , May 25, 2018 |  BC Week In Review  |  Clinical News

Keytruda improves survival in first-line squamous NSCLC

Merck & Co. Inc. (NYSE:MRK) said Keytruda pembrolizumab plus chemotherapy met the primary endpoints of improving progression-free survival (PFS) and overall survival (OS) in the Phase III KEYNOTE-407 trial as first-line treatment of metastatic squamous...